## TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT Docket No. . (Under 37 CFR 1.97(b) or 1.97(c)) 323-100 US D In Re Application Of: SUZANNE ZEBEDEE, ET. AL. Application No. Customer No. Group Art Unit Confirmation No. Filing Date Examiner 10/01/2003 ZACHARIAH LUCAS NONE 1648 9260 10/677,956 Title: AND SYSTEMS FOR PRODUCING RECOMBINANT VIRAL ANTIGENS Address to: **Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450 37 CFR 1.97(b) 1. Mark The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114. 37 CFR 1.97(c) 2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: ☐ the statement specified in 37 CFR 1.97(e); OR the fee set forth in 37 CFR 1.17(p).

## TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT Docket No. (Under 37 CFR 1.97(b) or 1.97(c)) 323-100 US D In Re Application of: SUZANNE ZEBEDEE, ET. AL. Group Art Unit Customer No. Confirmation No. Application No. Filing Date Examiner ZACHARIAH LUCAS NONE 1648 9260 10/677,956 10/01/2003 NOD AND SYSTEMS FOR PRODUCING RECOMBINANT VIRAL ANTIGENS FEB 1 3 2006 Payment of Fee (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p)) A check in the amount of is attached. The Director is hereby authorized to charge and credit Deposit Account No. 13-4892 as described below. Charge the amount of П Credit any overpayment. Charge any additional fee required. ☐ Payment by credit card. Form PTO-2038 is attached. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. Certificate of Mailing by First Class Mail Certificate of Transmission by Facsimile\* I hereby certify that this correspondence is being deposited I certify that this document and authorization to charge deposit with the United States Postal Service with sufficient postage account is being facsimile transmitted to the United States as express, mail in an envelope addressed to Patent and Trademark Office (Fa "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on February 13, 2006 (Date) (Date) Signature of Person Mailing Correspondence Signature Sally Shore Typed or Printed Name of Person Mailing Certificate Typed or Printed Name of Person Signing Certificate \*This certificate may only be used if paying by deposit account. Dated: February 13, 2006 Signature JOSEPH E-MUETH, ESQ. JOSEPH E. MUETH LAW CORPORATION 225 S. LAKE AVENUE, 8TH FLOOR PASADENA, CALIFORNIA 91101 TELEPHONE: (626) 584-0396 FACSIMILE: (626) 584-6862 CC:

Under the Paperwork Reduction Act of 1990, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for fo	orm	1449A/PTÓ
------------	--------	-----	-----------

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

1 of 2

Co	Complete if Known		
Application Number	10/677,956		
Filing Date	10/01/2003		
First Named Inventor	Suzanne Zebedee		
Art Unit	1648		
Examiner Name	Zachariah Lucas		
Attorney Docket Number	323-100US D		

**U.S. PATENT DOCUMENTS** Pages, Columns, Lines, Where Document Number Name of Patentee or amine Cite **Publication Date** Relevant Passages or Relevant Applicant of Cited Document MM-DD-YYYY Figures Appear No.1 Number-Kind Code 2 (if k US-

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Doo Country Code <sup>3</sup> Number <sup>4</sup>	Kind Code <sup>5</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	т6
	1101	EP 0363 025 B1	(if known)	9/12/1989	Arima, T., et al.	Figures Appear entire document	+
		0 377 303 B1		12/20/1989	Mishiro, S., et al.	entire document	
		0 388 232 A1		3/16/1990	Houghton, M., et. al.	entire document	
							+
							+

Examiner	Date	
Signature	Considered	<u> </u>

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449B/PTO 10/677,956 Application Number INFORMATION DISCLOSURE Filing Date 10/01/2003 STATEMENT BY APPLICANT First Named Inventor Suzanne Zebedee Art Unit 1648 (Use as many sheets as necessary) Examiner Name Zachariah Lucas of Sheet 2 Attorney Docket Number 323-100US D

	1	NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		WILKINS, J., "Late seroconversion following HPV -77, DE5 rubella virus vaccine", Am. J. Obstet. Gynecol., Vol. 121, No. 7, pp. 998-1002 (1974)	
		ALLAIN, J. P., ET AL., "Seriological Markers In Early Stages Of Human Immunodeficiency Virus Infection In Haemophiliacs", The Lancet, pp. 1233-1236 (11/29/1986)	
		FARZADEGAN, H., ET AL., "Performance of Serological Assays for Early Detection of Human Immunodeficiency Virus Type 1 Seroconversion", J. of Clin. Microbio., Vol. 27, No. 8, pp. 1882-1884 (1989)	
		ALTER, H. J., ET AL., "Detection Of Antibody To Hepatitis C Virus In Prospectively Followed Transfusion Recipients With Acute And Chronic Non-A, Non-B Hepatitis", New. Eng. J. of Med., Vol. 321, No. 22, pp. 1494-1500 (1990)	
		CHOO, Q-L., ET AL., "Hepatitis C virus: The major causative agent of viral non-A, non-B hepatitis", Br. Med. Bull., Vol. 46, No. 2, pp. 423-441 (1990)	
		TAKEUCHI, K., ET AL., "The putative nucleocapsid and envelope protein genes of hepatitis C virus determined by comparison of the nucleotide sequences of two isolates derived from an experimentally infected chimpanzee and healthy human carriers", J. of Gen. Virology, Vol. 71, pp. 3027-3033 (1990)	
		OKAMOTO, H., ET AL., "The 5'-Terminal Sequence of the Hepatitis C Virus Genome", Jap. J. Exp. Med., Vol. 60, No. 3, pp. 167-177 (1990)	
		MAENO, M., ET AL., "A cNDA close closely associated with non-A, non-B hepatitis", Nucleic Acids Res., Vol. 18, No. 9, pp. 2685-2689 (1990)	
		WEINER, A.J., ET AL., "Variable and Hypervariable Domains Are Found in the Regions of HCV Corresponding to the Flavivirus Envelope and NS1 Proteins and the Pestivirus Envelope Glycoproteins", Virology, Vol. 180, pp. 842-848 (1991, accepted for publication 10/18/1990)	
Examine			<u>_</u>

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Considered

Signature

<sup>&</sup>lt;sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.